Physician profile
Joyce Feagin
NPI 1285660316
$18,641.79
in general payments reported to CMS, 2019-2025
40 companies · $4,272 in 2025
The $4,272 reported for 2025 was more than what 80% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,829 · 2020: $2,703 · 2021: $17.53 · 2022: $2,818 · 2023: $894 · 2024: $4,108 · 2025: $4,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,178 · Long Term Medical Supply Or Device Loan: $1,995 · Food and Beverage: $1,543 · Honoraria: $360 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,177.50 |
| Long Term Medical Supply Or Device Loan | $1,995.48 |
| Food and Beverage | $1,543.31 |
| Honoraria | $360.00 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $10,924.04 | 2019-2025 | Imfinzi, Calquence, Lynparza |
| Novartis Pharmaceuticals Corporation | $2,366.68 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,419.41 | 2019-2024 | Opdivo |
| Eisai INC. | $1,229.45 | 2019-2020 | |
| Daiichi Sankyo INC. | $566.49 | 2019-2025 | Enhertu, Injectafer |
| Abbvie INC. | $383.05 | 2019-2025 | |
| Janssen Biotech, INC. | $335.10 | 2019-2025 | Tecvayli, Darzalex, Talvey |
| Genzyme Corporation | $146.12 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $126.81 | 2019-2025 | Keytruda, Lynparza |
| Takeda Pharmaceuticals U.S.A., INC. | $124.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Pfizer INC. | $88.97 | 2019-2024 | |
| Myriad Genetic Laboratories, INC. | $83.31 | 2023 | Precisetumor |
| Genentech USA, INC. | $79.73 | 2019-2025 | Polivy, Tecentriq, Phesgo |
| Tempus Ai, INC | $72.61 | 2025 | Xt Cdx |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Feagin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.